Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunmax Biotechnology CoROCO:4728 +1.06%91 Altman Z-Score is 28.17 as of Jul. 13, 2026, which is 98% above its 10-year median of 14.23. GuruFocus rates ROCO:4728 with a GF Score™ of 91/100 and a GF Value™ of NT$441.22 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 928 Biotechnology companies, Sunmax Biotechnology Co ranks better than 91.06% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 27.91 is strong.
Sunmax Biotechnology Co has a Altman Z-Score of 28.17, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Sunmax Biotechnology Co's Altman Z-Score or its related term are showing as below:
ROCO:4728'
s Altman Z-Score Range Over the Past 10 Years
Min: 7.74 Med: 14.23 Max: 33.63
Current: 27.91
During the past 13 years, Sunmax Biotechnology Co's highest Altman Z-Score was 33.63. The lowest was 7.74. And the median was 14.23.
Sunmax Biotechnology Co (ROCO:4728) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4728 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Sunmax Biotechnology Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunmax Biotechnology Co Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunmax Biotechnology Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Sunmax Biotechnology Co's Altman Z-Score falls into.
Sunmax Biotechnology Co Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Sunmax Biotechnology Co (ROCO:4728) has a Altman Z-Score of 28.17 as of Jul. 13, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sunmax Biotechnology Co and its competitors. This is 98% above median its historical median of 14.23. Over the past decade, Sunmax Biotechnology Co's Altman Z-Score has ranged from 7.74 to 33.63. According to the industry distribution chart, Sunmax Biotechnology Co ranks #83 out of 928 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Sunmax Biotechnology Co's Altman Z-Score too high?
Sunmax Biotechnology Co's current Altman Z-Score of 28.17 is 98% above median its 10-year median of 14.23. Over the past 10 years, this metric has ranged from a low of 7.74 to a high of 33.63. The Biotechnology industry median Altman Z-Score is 2.69. Sunmax Biotechnology Co's value of 28.17 is 947.2% above this industry median. Based on the distribution chart, Sunmax Biotechnology Co ranks #83 out of 928 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sunmax Biotechnology Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunmax Biotechnology Co's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunmax Biotechnology Co ranks #83 out of 928 companies for Altman Z-Score. This places Sunmax Biotechnology Co in the top 9% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.69. Sunmax Biotechnology Co's value of 28.17 is 947.2% above this benchmark. Historically, Sunmax Biotechnology Co's own Altman Z-Score has ranged from 7.74 to 33.63 over the past decade. While the company's 10-year median is 14.23 vs. the industry median of 2.69, Sunmax Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.69, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunmax Biotechnology Co's current Altman Z-Score of 28.17 is 947.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sunmax Biotechnology Co and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunmax Biotechnology Co's current Altman Z-Score is 28.17, which is 98% above median its own 10-year median of 14.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunmax Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Sunmax Biotechnology Co (ROCO:4728) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$441.22, compared to a current price of NT$381.00 — trading 13.6% below its estimated fair value. The current Altman Z-Score is 28.17, which is 98% above median its 10-year median of 14.23 and 947.2% above the Biotechnology industry median of 2.69. Sunmax Biotechnology Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Sunmax Biotechnology Co (ROCO:4728), the current Altman Z-Score is 28.17 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunmax Biotechnology Co (ROCO:4728) Overvalued in 2026?
Based on GuruFocus' analysis, Sunmax Biotechnology Co stock appears to be undervalued.
The current stock price of NT$381.00 is trading 13.6% below its estimated GF Value™ of NT$441.22.
GuruFocus considers Sunmax Biotechnology Co to be Modestly Undervalued.
Key valuation signals for ROCO:4728:
Altman Z-Score: 28.17 (98% above median its 10-year median of 14.23)
GF Value™: NT$441.22 vs. price of NT$381.00 (13.6% below fair value)
Industry Position: 947.2% above the Biotechnology median (#83 of 928)
No single metric tells the full story. See the ROCO:4728 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
91GF Score
Get the complete analysis for ROCO:4728
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4728 has been successfully added to your 
